Cerus (CERS) Cash from Operations Growth (3y) (2013 - 2026)
Cerus (CERS) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.40 Bn | 176.11 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.93 Bn | 126.05 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.35 Bn | 99.13 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.71 Bn | 67.25 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.68 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 28.04 Bn | 25.76 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 0.50% |
| 10 | Cerus | 602.81 Mn | 522.39 Mn | 27.89 Mn | 28.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.95% |
| Dec 31, 2025 | 76.85% |
| Sep 30, 2025 | 43.20% |
| Jun 30, 2025 | -92.11% |
| Mar 31, 2025 | 65.99% |
| Dec 31, 2024 | 82.05% |
| Sep 30, 2024 | 37.83% |
| Jun 30, 2024 | 26.96% |
| Mar 31, 2024 | 28.31% |
| Dec 31, 2023 | -19.48% |
| Sep 30, 2023 | -26.44% |
| Jun 30, 2023 | -4.34% |
| Mar 31, 2023 | 24.57% |
| Dec 31, 2022 | 40.23% |
| Sep 30, 2022 | 54.75% |
| Jun 30, 2022 | 70.08% |
| Mar 31, 2022 | 1.10% |
| Dec 31, 2021 | 44.36% |
| Sep 30, 2021 | -10.37% |
| Jun 30, 2021 | 1.01% |